Discern has served as an advisor and subject matter expert for our clients’ multiple cclerosis (MS) quality and performance measurement initiatives. Using a multi-pronged approach to measure development, implementation, and quality improvement, Discern has supported coordination of activities among stakeholders through national health care organizations including the Pharmacy Quality Alliance (PQA), the National Quality Forum (NQF), the American Academy of Neurology (AAN), and the Physician Consortium for Performance Improvement (PCPI). Through this collaboration, four MS measures have been developed by PQA and are being field tested. One measure focuses on the use of Disease Modifying Therapy (DMT) and three measures focus on Magnetic Resonance Imaging (MRI) for MS care and treatment monitoring. Separately, the NQF Measure IncubatorTM has been engaged to develop an MS patient-reported measure. Once the measures are finalized, Discern will assist in promoting uptake of the measures through implementation in programs. Discern has also been involved in efforts to educate the MS patient advocacy community on the health care quality landscape, with a specific focus on quality measurement. The goal of the collective MS measurement work is improved care and outcomes for patients with MS.